{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:10:27Z","timestamp":1784783427369,"version":"3.55.0"},"reference-count":111,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>Hypertension is the single most important modifiable risk factor for preventable disability and death worldwide and disproportionately affects socially disadvantaged populations. We face a paradox\u2014blood pressure control is low and recent trends suggest it is even declining, despite the availability of inexpensive and effective therapies. A variety of barriers on the system, patient, and healthcare provider side hinder effective drug-based risk factor management. Clinical inertia represents a major barrier on the clinician side, as well as workload and limited education. Common barriers on the patient side include limited English proficiency, low health literacy, and nonadherence with misaligned incentives, limited resources, lack of structured clinical pathways, and reimbursement issues. New innovations in the field of RNA-targeted therapies and device-based interventions could prevent and potentially even cure diseases previously designated as chronic health conditions, such as hypertension. Such novel therapies could potentially overcome several major barriers to effective treatment, including nonadherence. Drug development of novel, long-acting treatments requires consideration of specific clinical trial design aspects, including safety collection, benefit: risk assessment, the development and assessment of novel, qualitative surrogate end points, such as time-in-therapeutic range, the use of representative trial settings as well as the definition of standard of care in placebo-controlled trials, which should be of reasonably high-quality allowing for credible evaluation of effectiveness. Here, we provide an overview on barriers to effective treatment and a framework for trials assessing novel treatments for cardiovascular disease risk factors, including early and broad implementation programs.<\/jats:p>","DOI":"10.1161\/hypertensionaha.125.24992","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T09:00:13Z","timestamp":1756198813000},"page":"1599-1611","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension"],"prefix":"10.1161","volume":"82","author":[{"given":"Konstantin A.","family":"Krychtiuk","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC (K.A.K., R.D.L., J.B.G., N.J.P., A.F.H., C.B.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-4961","authenticated-orcid":true,"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC (K.A.K., R.D.L., J.B.G., N.J.P., A.F.H., C.B.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria A","family":"Cargill","sequence":"additional","affiliation":[{"name":"Center for Public Health, Milken Institute, Washington, DC (V.A.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Chen","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, NJ (R.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7457-2552","authenticated-orcid":true,"given":"Martin R.","family":"Cowie","sequence":"additional","affiliation":[{"name":"Late-Stage Development, Cardiovascular, Renal and Metabolic, BioPharmaceuticals R&amp;D, AstraZeneca, Boston, MA (M.R.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7162-2972","authenticated-orcid":true,"given":"William C.","family":"Cushman","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis (W.C.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2562-1156","authenticated-orcid":true,"given":"Mitchell S.V.","family":"Elkind","sequence":"additional","affiliation":[{"name":"American Heart Association, Dallas, TX (M.S.V.E., E.S.)."},{"name":"Columbia University, New York, NY (M.S.V.E.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpi","family":"Epstein","sequence":"additional","affiliation":[{"name":"Bayer, Whippany, NJ (S.E.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushkal P.","family":"Garg","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA (P.P.G., W.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5605-900X","authenticated-orcid":true,"given":"Bernard J.","family":"Gersh","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN (B.J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-9823","authenticated-orcid":true,"given":"Michail","family":"Giakoumis","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA (M.G., E.M.O.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9967-5352","authenticated-orcid":true,"given":"Jennifer B.","family":"Green","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC (K.A.K., R.D.L., J.B.G., N.J.P., A.F.H., C.B.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weinong","family":"Guo","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA (P.P.G., W.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0061-1058","authenticated-orcid":true,"given":"Ajay J.","family":"Kirtane","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center\/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation (A.J.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8830-6316","authenticated-orcid":true,"given":"Marty","family":"Lefkowitz","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Corporation, East Hanover, NJ (M.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Lesogor","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland (A.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0387-5326","authenticated-orcid":true,"given":"George A.","family":"Mensah","sequence":"additional","affiliation":[{"name":"Center for Translation Research and Implementation Science, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (G.A.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8663-0067","authenticated-orcid":true,"given":"Michelle L.","family":"O\u2019Donoghue","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA (M.L.O.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6249-4988","authenticated-orcid":true,"given":"E. Magnus","family":"Ohman","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA (M.G., E.M.O.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5004-8868","authenticated-orcid":true,"given":"Neha J.","family":"Pagidipati","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC (K.A.K., R.D.L., J.B.G., N.J.P., A.F.H., C.B.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reboussin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC (D.R.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Roessig","sequence":"additional","affiliation":[{"name":"Bayer AG, Leverkusen, Germany (L.R.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-7865","authenticated-orcid":true,"given":"Veronique L.","family":"Roger","sequence":"additional","affiliation":[{"name":"Epidemiology and Community Health Branch, National Heart Lung and Blood Institute, Bethesda, MD (V.L.R.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8948-4456","authenticated-orcid":true,"given":"Eduardo","family":"Sanchez","sequence":"additional","affiliation":[{"name":"American Heart Association, Dallas, TX (M.S.V.E., E.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8079-0263","authenticated-orcid":true,"given":"Norman","family":"Stockbridge","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD (N.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0670-0887","authenticated-orcid":true,"given":"Rhian M","family":"Touyz","sequence":"additional","affiliation":[{"name":"Research Institute of the McGill University Health Centre (RI-MUHC), Department of Medicine, Faculty of Medicine and Health Sciences (R.M.T.), Research Institute of St. Joseph\u2019s, McMaster University, Hamilton, Ontario, Canada."},{"name":"Department of Family Medicine, Faculty of Medicine and Health Sciences (R.M.T.), Research Institute of St. Joseph\u2019s, McMaster University, Hamilton, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-4569","authenticated-orcid":true,"given":"Harriette G.C.","family":"Van Spall","sequence":"additional","affiliation":[{"name":"McGill University, Montreal, Quebec, Canada. Department of Medicine (H.G.C.V.S.), Research Institute of St. Joseph\u2019s, McMaster University, Hamilton, Ontario, Canada."},{"name":"Department of Health Research Methods, Evidence, and Impact (H.G.C.V.S.), Research Institute of St. Joseph\u2019s, McMaster University, Hamilton, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8504-0831","authenticated-orcid":true,"given":"Michael A.","family":"Weber","sequence":"additional","affiliation":[{"name":"State University of New York, Downstate College of Medicine, New York, NY (M.A.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5914-0735","authenticated-orcid":true,"given":"Seamus P.","family":"Whelton","sequence":"additional","affiliation":[{"name":"Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD (S.P.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-9616","authenticated-orcid":true,"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC (K.A.K., R.D.L., J.B.G., N.J.P., A.F.H., C.B.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7271-4166","authenticated-orcid":true,"given":"Clyde W.","family":"Yancy","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, IL (C.W.Y.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0045-3291","authenticated-orcid":true,"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC (K.A.K., R.D.L., J.B.G., N.J.P., A.F.H., C.B.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.11.007"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.02.048"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.008506"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvac052"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024785"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.053461"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.05.033"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000753"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.14545"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511939"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2022.3345"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2017.01.007"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0476"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2283"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.32.3.97"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220857"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.2854"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.20292"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/M17-1805"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2014.03.004"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae178"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000065"},{"key":"e_1_3_3_24_2","unstructured":"CDC: team-based care to improve blood pressure control. Accessed May 20 2025. https:\/\/www.cdc.gov\/high-blood-pressure\/php\/data-research\/team-based-care\/index.html"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.13616"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000203"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aap9559"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv641"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3953"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S429638"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00876-5"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/circoutcomes.116.003166"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.49930"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.2640"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac810"},{"key":"e_1_3_3_36_2","unstructured":"IQVIA Institute. Advancing diversity in clinical development through cross-stakeholder commitment and action. Accessed December 19 2022. https:\/\/secure.constellation.iqvia.com\/clinical-trial-diversity-report?utm_campaign=2022_ClinicalTrialDiversityreport_Institute_TC&utm_medium=email&utm_source=Eloqua"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2101627"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.14059"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0754-2"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-5121-6"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1717250"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.004691"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30309-X"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01744-6"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.05.050"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.3606"},{"key":"e_1_3_3_47_2","unstructured":"United States Code title 21\u2014food and drugs; chapter 9 subcharter V part A section 355\u2014new drugs. Accessed August 15 2025. https:\/\/www.govinfo.gov\/app\/details\/USCODE-2010-title21\/USCODE-2010-title21-chap9-subchapV-partA-sec355"},{"key":"e_1_3_3_48_2","unstructured":"Food and Drug Administration. Table of surrogate endpoints that were the basis of drug approval or licensure. Accessed April 16 2023. https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2021.04.004"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.06.039"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2024.01.004"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001286"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009326"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2412006"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01028-6"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.18865\/ed.26.3.369"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2022.4018"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.4390"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212270"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.0720"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.5129"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.025"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.18080"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213169"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02034-7"},{"key":"e_1_3_3_66_2","unstructured":"Kumbhani DJ Eagle KA. Efficacy and safety of baxdrostat in patients with uncontrolled hypertension\u2014HALO. Accessed October 11 2023. https:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2023\/03\/01\/23\/34\/halo"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.16029"},{"key":"e_1_3_3_68_2","unstructured":"American Heart Association. First-in-class aminopeptidase-A inhibitor fails to reduce treatment-resistant hypertension. Accessed October 11 2023. https:\/\/sessions.hub.heart.org\/aha-22\/article\/22539144\/firstinclass-aminopeptidasea-inhibitor-fails-to-reduce-treatmentresistant-hypertension"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00676-2"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501440"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208391"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0728"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.6681"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.06.019"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402670"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.0338"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.2106"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.05.001"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.1150"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2014.0516"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.22582"},{"key":"e_1_3_3_82_2","unstructured":"Caffrey M. Cigna reaches pay-for-performance deals for PCSK9 inhibitors. Accessed December 16 2022. https:\/\/www.ajmc.com\/view\/cigna-reaches-pay-for-performance-deals-for-pcsk9-inhibitors"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.15782"},{"key":"e_1_3_3_84_2","unstructured":"TCTMD. Pricey inclisiran is rolling out: a \u201cbuy-and-bill\u201d model may smooth its path. Accessed May 26 2023. https:\/\/www.tctmd.com\/news\/pricey-inclisiran-rolling-out-buy-and-bill-model-may-smooth-its-path"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.99B11.BJJ-2017-0647"},{"key":"e_1_3_3_86_2","unstructured":"National Institute for Health and Care Excellence (NICE). Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. Technology appraisal guidance [TA733]. Accessed December 16 2022. https:\/\/www.nice.org.uk\/guidance\/ta733"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad150"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2021.1905000"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.122.009321"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-021-01584-2"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2025.03.005"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10900-018-0547-4"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.15243"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.0511"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj080117"},{"key":"e_1_3_3_96_2","unstructured":"Food and Drug Administration. International regulatory harmonization. Accessed December 16 2022. https:\/\/www.fda.gov\/drugs\/cder-international-program\/international-regulatory-harmonization"},{"key":"e_1_3_3_97_2","unstructured":"Food and Drug Administration. Determining the extent of safety data collection needed in late-stage premarket and postapproval clinical investigations\u2013guidance for industry. Accessed May 30 2023. https:\/\/www.fda.gov\/files\/drugs\/published\/Determining-the-Extent-of-Safety-Data-Collection-Needed-in-Late-Stage-Premarket-and-Postapproval-Clinical-Investigations.pdf"},{"key":"e_1_3_3_98_2","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). E19 a selective approach to safety data collection in specific late-stage preapproval or post-approval clinical trials. Accessed May 30 2023. https:\/\/www.fda.gov\/media\/163670\/download"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.061620"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.008857"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.006606"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901183"},{"key":"e_1_3_3_104_2","unstructured":"Food and Drug Administration. Framework for FDA\u2019s real-world evidence program. Accessed October 11 2023. https:\/\/www.fda.gov\/media\/120060\/download"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2883"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.11.1233"},{"key":"e_1_3_3_107_2","unstructured":"DCRI Think Tanks: addressing clinical trial deserts. Accessed May 31 2023. https:\/\/dcri.org\/sites\/default\/files\/2024-06\/addressing-clinical-trial-deserts-executive-summary.pdf"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad171"},{"key":"e_1_3_3_109_2","unstructured":"National Health Service. NHS cholesterol-busting jab to save thousands of lives. Accessed December 16 2022. https:\/\/www.england.nhs.uk\/2021\/09\/nhs-cholesterol-busting-jab-to-save-thousands-of-lives\/"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2143"},{"key":"e_1_3_3_111_2","unstructured":"NHS England. Funding and supply of inclisiran (Leqvio\u00ae). Accessed May 18 2025. https:\/\/www.england.nhs.uk\/long-read\/funding-supply-inclisiran-leqvio\/"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p1757"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.125.24992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T18:02:46Z","timestamp":1779300166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.125.24992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":111,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.125.24992"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.125.24992","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}